A phase I and pharmacokinetic study of afilbercept with FOLFIRI: comparison of Chinese and Caucasian populations

Jianming Xu(Chinese PLA General Hospital), Rui‐Hua Xu(Sun Yat-sen University), Fengying Xue(Sanofi (China)), Samira Ziti‐Ljajic(Sanofi (France)), Dongmei Shi(Weifang University), Dongsheng Zhang(Sun Yat-sen University), Yingxin Li(Guangxi Medical University), N Le Bail, Xing Sun(Sanofi (United States)), Rongrui Liu(Chinese PLA General Hospital)

Investigational New Drugs

January 19, 2017

10.1007/s10637-016-0421-0

Cited by 4

Related Papers

Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer

|Journal of Clinical Oncology|2000|3.8k

Circular RNA: metabolism, functions and interactions with proteins

|Molecular Cancer|2020|1.6k

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

|The Lancet|2012|1.4k

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction

|Journal of Clinical Oncology|2016|1k

METTL3 facilitates tumor progression via an m6A-IGF2BP2-dependent mechanism in colorectal carcinoma

|Molecular Cancer|2019|868